SEPTInvestingStart Free

BBIO SCHEDULE 13D/A: SEC filing

KKR & Co. Inc.

Filed with the SEC on · accession 0001140361-26-033404

BBIO filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Aug 17, 2026. KKR & Co. Inc. filed an amendment to its Schedule 13D regarding its stake in BridgeBio Pharma, Inc., including an exhibit listing KKR's directors. The stock moved +0.0% by the first close after the filing.

Summary of the filing

KKR & Co. Inc. filed an amendment to its Schedule 13D regarding its stake in BridgeBio Pharma, Inc., including an exhibit listing KKR's directors. The filing does not disclose any change in ownership or new plans for the company.

For details, click here →

Key details

Filer/beneficial ownerKKR & Co. Inc.
Subject companyBridgeBio Pharma, Inc.
Co-executive chairman of kkr & co. inc.Henry R. Kravis
Co-executive chairman of kkr & co. inc.George R. Roberts
Co-chief executive officer of kkr & co. inc.Joseph Y. Bae
Co-chief executive officer of kkr & co. inc.Scott C. Nuttall

How BBIO stock reacted

Close before

$79.86

Aug 14, 2026

First close after

+0.04%

$79.89

5 trading days

+2.05%

$81.50

Since filing

-6.97%

$74.29

✦ Ask GOAX AI about this filing — what it means for BBIO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BBIO?

Click here

Frequently asked questions

What did BBIO file with the SEC on Aug 17, 2026?

BBIO filed a SCHEDULE 13D/A (SEC filing). KKR & Co. Inc. filed an amendment to its Schedule 13D regarding its stake in BridgeBio Pharma, Inc., including an exhibit listing KKR's directors. The filing does not disclose any change in ownership or new plans for the company.

How do I read a SCHEDULE 13D/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).

How did BBIO stock react to this filing?

BBIO closed at $79.86 before the filing and $79.89 on Aug 17, 2026 (+0.04%). Five trading days later: $81.50 (+2.05%).

Other BBIO SEC filings

Get alerts when BBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BBIO overviewBBIO analysisBBIO newsLatest SEC filings